Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LUPKYNIS vs PIMECROLIMUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcineurin inhibitor immunosuppressant that binds to cyclophilin A, inhibiting calcineurin activity, which prevents dephosphorylation and activation of nuclear factor of activated T-cells (NFAT), thereby reducing cytokine production and T-cell activation.
Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.
Treatment of lupus nephritis in combination with a background immunosuppressive therapy
Mild to moderate atopic dermatitis in immunocompetent patients aged 2 years and older,Off-label: psoriasis, seborrheic dermatitis, vitiligo, lupus erythematosus
23.7 mg orally twice daily with food.
Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.
Terminal elimination half-life approximately 30 hours; supports once-daily dosing; steady-state reached by day 4.
Terminal elimination half-life is approximately 65 hours (range 22–115 hours) in adult atopic dermatitis patients, reflecting slow systemic clearance.
Primarily metabolized by CYP3A4; minor contribution from CYP3A5.
Primarily metabolized via hepatic cytochrome P450 3A4 (CYP3A4) to O-demethylated metabolites; also undergoes further hydroxylation and glucuronidation.
Primarily hepatic metabolism; <1% excreted unchanged in urine; approximately 66% of total radioactivity recovered in feces (mainly metabolites) and 22% in urine (mainly metabolites).
Primarily fecal (78.4% of dose) via biliary excretion; renal elimination accounts for <1% of unchanged drug.
Greater than 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
99.5% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Apparent Vd/F ~24 L (approximately 0.34 L/kg assuming 70 kg); indicates distribution into tissues.
Approximately 1.3 L/kg (range 0.6–2.1 L/kg), indicating extensive tissue distribution.
Oral bioavailability approximately 35% (range 20–50%) under fasting conditions; high-fat meal reduces Cmax and AUC by about 50%.
Topical: Systemic bioavailability is very low (<0.5% of applied dose) based on blood concentration measurements.
No dose adjustment required for GFR ≥30 m L/min. Avoid use in severe renal impairment (GFR <30 m L/min) due to lack of data.
No dose adjustment required for renal impairment; systemic absorption is minimal (<2.5%).
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 15.8 mg orally twice daily. Child-Pugh Class C: Not recommended.
No formal studies in hepatic impairment; based on minimal systemic absorption, no adjustment is likely required, but use caution in severe hepatic impairment due to theoretical risk of increased exposure.
Safety and efficacy not established in pediatric patients; no approved dose.
Children ≥2 years: Apply a thin layer of 1% cream to affected areas twice daily; maximum application area: <20% body surface area. Avoid use in children <2 years due to risk of systemic effects (insufficient data).
No specific dose adjustment required; monitor renal function due to age-related decline.
No specific dose adjustment; use lowest effective amount due to potential for increased skin sensitivity and renal function decline with age.
Increased risk of infection and lymphoma; increased risk of nephrotoxicity and hypertension; increased risk of neurotoxicity.
Long-term safety of topical calcineurin inhibitors has not been established; rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported; avoid continuous long-term use; limit use to indicated short-term and intermittent treatment.
Nephrotoxicity and hypertension require regular monitoring. Neurotoxicity including posterior reversible encephalopathy syndrome (PRES). Increased susceptibility to infections including opportunistic infections. Malignancies including lymphoma. Monitor for Epstein-Barr virus serology. Use with caution with CYP3A4 inhibitors and inducers. Avoid live vaccines.
Increased risk of infections (e.g., varicella zoster, herpes simplex); avoid use on active infections; possible lymphadenopathy; photosensitivity (avoid UV exposure); monitor for skin atrophy; not recommended in children <2 years; use during pregnancy only if clearly needed.
Concurrent use with chronic immunosuppressive therapies other than mycophenolate mofetil (MMF) or mycophenolic acid (MPA). Known hypersensitivity to voclosporin or any component of the formulation.
History of hypersensitivity to pimecrolimus or any component of the formulation; Netherton syndrome; generalized erythroderma; active viral, bacterial, or fungal skin infections at application site.
Avoid grapefruit and grapefruit juice as they increase voclosporin exposure. No other specific food interactions are known.
No known food interactions with topical pimecrolimus. Oral ingestion should be avoided; however, accidental small amounts on skin are unlikely to cause systemic effects.
LUPKYNIS (voclosporin) is a calcineurin inhibitor. Based on animal studies, there is a risk of fetal harm in all trimesters. In rats and rabbits, voclosporin administration during organogenesis resulted in increased embryofetal mortality and reduced fetal weight at maternally toxic doses. There are no adequate human studies. Avoid use during pregnancy unless potential benefit outweighs risk.
Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: theoretical risk due to systemic absorption; avoid if possible. Second and third trimesters: limited data; risk of fetal harm cannot be excluded.
It is unknown if voclosporin is excreted in human milk. In animal studies, voclosporin and its metabolites were detected in milk of lactating rats. No M/P ratio available for humans. Due to potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment and for 4 weeks after last dose.
It is not known whether pimecrolimus is excreted in human milk. Systemic absorption after topical application is minimal (<2.5 ng/m L), suggesting negligible transfer. However, due to potential for serious adverse reactions in nursing infants, caution should be exercised. M/P ratio is not available. Breastfeeding is generally considered acceptable with cautious use.
No specific dose adjustments are established for pregnancy. However, pregnancy can increase voclosporin clearance due to expanded plasma volume and enhanced metabolism. Consider therapeutic drug monitoring if available, and adjust dose to maintain therapeutic trough levels (target 30-60 ng/m L) as needed.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy. Use the minimum amount necessary to control symptoms, and avoid application to large body surface areas or prolonged use. Systemic absorption is minimal and unlikely to be altered significantly during pregnancy.
Monitor for hematuria, proteinuria, and e GFR during treatment. Lupkynis (voclosporin) is a calcineurin inhibitor; do not co-administer with other CNIs or strong CYP3A4 inhibitors. Reduce dose in patients with e GFR <45 m L/min per 1.73 m². Concomitant use with mycophenolate mofetil and corticosteroids is standard. Check blood pressure and serum potassium regularly. Live vaccines contraindicated.
Pimecrolimus is a topical calcineurin inhibitor used for mild-to-moderate atopic dermatitis. It is not indicated for use in children under 2 years. Avoid use on infected skin; monitor for local irritation. Long-term safety concerns include potential increased risk of lymphoma and skin malignancies; use minimal amounts for shortest duration necessary. Do not use with occlusive dressings. Consider intermittent therapy for flares.
Take exactly as prescribed; do not stop or change dose without consulting your doctor.,You will need regular blood and urine tests to monitor kidney function and drug levels.,Report any signs of infection (fever, sore throat), high blood pressure (severe headache, vision changes), or changes in urine output/color.,Avoid grapefruit and grapefruit juice during treatment.,Do not receive live vaccines while taking this medication.,Use effective contraception during treatment and for 12 weeks after last dose if of childbearing potential.,Tell your doctor about all medications, including over-the-counter drugs and supplements.
Apply a thin layer only to affected areas, avoiding eyes, mouth, and broken skin.,Do not cover treated area with bandages or wraps unless directed by your doctor.,Wash hands after applying unless treating hands.,Avoid sun exposure, tanning beds, and UV therapy while using this medication.,Report any signs of infection, skin burning, or worsening rash.,Do not use for prolonged periods; use only until symptoms clear.,Inform your doctor if you are pregnant, breastfeeding, or have a weakened immune system.
No interactions on record
"Pimecrolimus, a calcineurin inhibitor, and panobinostat, a histone deacetylase inhibitor, both have immunosuppressive and potential myelosuppressive effects. Concurrent use may synergistically increase the risk of infections, including opportunistic infections, and hematologic toxicities such as neutropenia, thrombocytopenia, and anemia. Additionally, both drugs can prolong the QT interval, potentially increasing the risk of serious cardiac arrhythmias like torsade de pointes."
"Pimecrolimus, a calcineurin inhibitor used topically, can inhibit CYP3A4 activity to a mild degree, potentially decreasing the metabolism of nilotinib, a BCR-ABL tyrosine kinase inhibitor that is predominantly metabolized by CYP3A4. This may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, hepatotoxicity, and other dose-related adverse effects. Therefore, patients should be carefully monitored for signs of nilotinib toxicity."
"Pimecrolimus and sirolimus both suppress immune function via distinct but overlapping mechanisms. Pimecrolimus inhibits calcineurin, reducing T-cell activation, while sirolimus inhibits mTOR, blocking cytokine-driven T-cell proliferation. Concomitant use increases the risk of over-immunosuppression, leading to higher susceptibility to infections, lymphoproliferative disorders, and possibly nephrotoxicity."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LUPKYNIS vs PIMECROLIMUS, answered by our medical review team.
LUPKYNIS is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor immunosuppressant that binds to cyclophilin A, inhibiting calcineurin activity, which prevents dephosphorylation and activation of nuclear factor of activated T-cells (NFAT), thereby reducing cytokine production and T-cell activation.. PIMECROLIMUS is a Calcineurin Inhibitor that works by Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LUPKYNIS and PIMECROLIMUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LUPKYNIS is: 23.7 mg orally twice daily with food.. The standard adult dose of PIMECROLIMUS is: Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LUPKYNIS and PIMECROLIMUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LUPKYNIS is classified as Category C. LUPKYNIS (voclosporin) is a calcineurin inhibitor. Based on animal studies, there is a risk of fetal harm in all trimesters. In rats and rabbits, voclosporin administration during . PIMECROLIMUS is classified as Category A/B. Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.